|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Other operating income, net | |||||
| Acquired in-process research and development | |||||
| Impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income, net | |||||
| Other (expense) income, net | |||||
| Impairment of other investments | |||||
| Total other (loss) income, net | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Net unrealized (loss) gain on marketable securities | |||||
| Comprehensive loss | |||||
| Net loss per common share, basic (in dollars per share) | |||||
| Net loss per common share, diluted (in dollars per share) | |||||
| Weighted-average shares used to compute net loss per common share, basic (in shares) | |||||
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | |||||
Loading...